Ascendis Pharma A/S and Supernus Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis

Biopharma Revenue Surge: Ascendis vs. Supernus (2014-2023)

__timestampAscendis Pharma A/SSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 201413983000122045000
Thursday, January 1, 20158118000144427000
Friday, January 1, 20164606000215003000
Sunday, January 1, 20171530000302238000
Monday, January 1, 201810581000408897000
Tuesday, January 1, 201913375000392755000
Wednesday, January 1, 20206953000520397000
Friday, January 1, 20217778000579775000
Saturday, January 1, 202251174000667238000
Sunday, January 1, 2023266718000607521000
Monday, January 1, 2024363641000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biopharma Giants: Revenue Trends from 2014 to 2023

In the dynamic world of biopharmaceuticals, Ascendis Pharma A/S and Supernus Pharmaceuticals, Inc. have carved distinct paths over the past decade. Ascendis Pharma, with its innovative approach, saw a staggering 1,800% increase in revenue from 2014 to 2023, peaking at $267 million in 2023. Meanwhile, Supernus Pharmaceuticals demonstrated steady growth, with revenues climbing by 400% to reach $608 million in the same year.

Key Insights

  • 2014-2018: Supernus consistently outperformed Ascendis, maintaining a revenue lead of over 200%.
  • 2019-2023: Ascendis experienced a breakthrough, with a remarkable surge in 2023, closing the gap significantly.

These trends highlight the evolving landscape of the biopharma industry, where innovation and strategic growth play pivotal roles in shaping financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025